{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:07:42Z","timestamp":1791439662211,"version":"4.3.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40263-024-01086-z","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T12:01:36Z","timestamp":1712491296000},"page":"481-491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5300-3983","authenticated-orcid":false,"given":"Amira","family":"Salim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Sonneborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-3831","authenticated-orcid":false,"given":"Olivia","family":"Hogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipa","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MaryAnn","family":"Mays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarushi","family":"Suneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubair","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-0633","authenticated-orcid":false,"given":"Ignacio F.","family":"Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,7]]},"reference":[{"issue":"4","key":"1086_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB. Migraine. Neurol Clin. 2019;37(4):631\u201349. https:\/\/doi.org\/10.1016\/j.ncl.2019.06.001.","journal-title":"Neurol Clin"},{"issue":"1","key":"1086_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s10194-023-01700-3","volume":"25","author":"M Leonardi","year":"2024","unstructured":"Leonardi M, Martelletti P, Burstein R, et al. The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders. J Headache Pain. 2024;25(1):4. https:\/\/doi.org\/10.1186\/s10194-023-01700-3.","journal-title":"J Headache Pain"},{"issue":"1","key":"1086_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s10194-023-01666-2","volume":"24","author":"P Martelletti","year":"2023","unstructured":"Martelletti P, Leonardi M, Ashina M, et al. Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030. J Headache Pain. 2023;24(1):140. https:\/\/doi.org\/10.1186\/s10194-023-01666-2.","journal-title":"J Headache Pain"},{"issue":"7","key":"1086_CR4","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/j.1526-4610.2009.01410.x","volume":"49","author":"M Bigal","year":"2009","unstructured":"Bigal M, Krymchantowski AV, Lipton RB. Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache. 2009;49(7):1028\u201341. https:\/\/doi.org\/10.1111\/j.1526-4610.2009.01410.x.","journal-title":"Headache"},{"issue":"6","key":"1086_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1086_CR6","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026\u201337. https:\/\/doi.org\/10.1177\/0333102418759786.","journal-title":"Cephalalgia"},{"key":"1086_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018. https:\/\/doi.org\/10.1212\/WNL.0000000000006640.","journal-title":"Neurology"},{"issue":"9","key":"1086_CR8","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212.","journal-title":"JAMA Neurol"},{"issue":"22","key":"1086_CR9","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1709038.","journal-title":"N Engl J Med"},{"issue":"3","key":"1086_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241\u201354. https:\/\/doi.org\/10.1177\/0333102420905132.","journal-title":"Cephalalgia"},{"key":"1086_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020. https:\/\/doi.org\/10.1212\/WNL.0000000000009169.","journal-title":"Neurology"},{"issue":"1","key":"1086_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J Headache Pain. 2022;23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x.","journal-title":"J Headache Pain"},{"issue":"2","key":"1086_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","volume":"24","author":"AS Wattiez","year":"2020","unstructured":"Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets. 2020;24(2):91\u2013100. https:\/\/doi.org\/10.1080\/14728222.2020.1724285.","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"1086_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1212\/WNL.0b013e31822550e2","volume":"77","author":"EE Benarroch","year":"2011","unstructured":"Benarroch EE. CGRP: sensory neuropeptide with multiple neurologic implications. Neurology. 2011;77(3):281\u20137. https:\/\/doi.org\/10.1212\/WNL.0b013e31822550e2.","journal-title":"Neurology"},{"issue":"2","key":"1086_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0304-3940(85)90166-1","volume":"58","author":"L Edvinsson","year":"1985","unstructured":"Edvinsson L, Fredholm BB, Hamel E, et al. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett. 1985;58(2):213\u20137. https:\/\/doi.org\/10.1016\/0304-3940(85)90166-1.","journal-title":"Neurosci Lett"},{"issue":"2","key":"1086_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183\u20137. https:\/\/doi.org\/10.1002\/ana.410280213.","journal-title":"Ann Neurol"},{"issue":"1","key":"1086_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"L Lassen","year":"2002","unstructured":"Lassen L, Haderslev P, Jacobsen V, et al. Cgrp may play a causative role in migraine. Cephalalgia. 2002;22(1):54\u201361. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00310.x.","journal-title":"Cephalalgia"},{"issue":"3","key":"1086_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/WCO.0000000000000440","volume":"30","author":"C Ram\u00f3n","year":"2017","unstructured":"Ram\u00f3n C, Cernuda-Moroll\u00f3n E, Pascual J. Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine. Curr Opin Neurol. 2017;30(3):281\u20136. https:\/\/doi.org\/10.1097\/WCO.0000000000000440.","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"1086_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1756285616677005","volume":"10","author":"CM Escher","year":"2017","unstructured":"Escher CM, Paracka L, Dressler D, et al. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord. 2017;10(2):127\u201335. https:\/\/doi.org\/10.1177\/1756285616677005.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"1086_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1067\/mhn.2000.110960","volume":"123","author":"WJ Binder","year":"2000","unstructured":"Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123(6):669\u201376. https:\/\/doi.org\/10.1067\/mhn.2000.110960.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"7","key":"1086_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"S Aurora","year":"2010","unstructured":"Aurora S, Dodick D, Turkel C, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793\u2013803. https:\/\/doi.org\/10.1177\/0333102410364676.","journal-title":"Cephalalgia"},{"issue":"7","key":"1086_CR22","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"H Diener","year":"2010","unstructured":"Diener H, Dodick D, Aurora S, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804\u201314. https:\/\/doi.org\/10.1177\/0333102410364677.","journal-title":"Cephalalgia"},{"issue":"1","key":"1086_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s10194-018-0921-8","volume":"19","author":"L Bendtsen","year":"2018","unstructured":"Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19(1):91. https:\/\/doi.org\/10.1186\/s10194-018-0921-8.","journal-title":"J Headache Pain"},{"issue":"6442","key":"1086_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/365160a0","volume":"365","author":"J Blasi","year":"1993","unstructured":"Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365(6442):160\u20133. https:\/\/doi.org\/10.1038\/365160a0.","journal-title":"Nature"},{"issue":"3","key":"1086_CR25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0022-5347(05)00322-8","volume":"175","author":"DE Rapp","year":"2006","unstructured":"Rapp DE, Turk KW, Bales GT, et al. Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol. 2006;175(3):1138\u201342. https:\/\/doi.org\/10.1016\/S0022-5347(05)00322-8.","journal-title":"J Urol"},{"issue":"3","key":"1086_CR26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1464-410X.2007.07312.x","volume":"101","author":"A Lucioni","year":"2008","unstructured":"Lucioni A, Bales GT, Lotan TL, et al. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101(3):366\u201370. https:\/\/doi.org\/10.1111\/j.1464-410X.2007.07312.x.","journal-title":"BJU Int"},{"issue":"7","key":"1086_CR27","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/head.13849","volume":"60","author":"R Burstein","year":"2020","unstructured":"Burstein R, Blumenfeld AM, Silberstein SD, et al. Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review. Headache. 2020;60(7):1259\u201372. https:\/\/doi.org\/10.1111\/head.13849.","journal-title":"Headache"},{"issue":"1","key":"1086_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1526-4610.2012.02262.x","volume":"53","author":"PL Durham","year":"2013","unstructured":"Durham PL, Masterson CG. Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment. Headache. 2013;53(1):67\u201380. https:\/\/doi.org\/10.1111\/j.1526-4610.2012.02262.x.","journal-title":"Headache"},{"issue":"11","key":"1086_CR29","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/0333102414527648","volume":"34","author":"R Burstein","year":"2014","unstructured":"Burstein R, Zhang X, Levy D, et al. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia. 2014;34(11):853\u201369. https:\/\/doi.org\/10.1177\/0333102414527648.","journal-title":"Cephalalgia"},{"issue":"9","key":"1086_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1177\/0333102416636843","volume":"36","author":"X Zhang","year":"2016","unstructured":"Zhang X, Strassman AM, Novack V, et al. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors\u2019 responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle? Cephalalgia. 2016;36(9):875\u201386. https:\/\/doi.org\/10.1177\/0333102416636843.","journal-title":"Cephalalgia"},{"issue":"11","key":"1086_CR31","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1177\/0333102419873675","volume":"39","author":"A Melo-Carrillo","year":"2019","unstructured":"Melo-Carrillo A, Strassman AM, Schain AJ, et al. Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. Cephalalgia. 2019;39(11):1358\u201365. https:\/\/doi.org\/10.1177\/0333102419873675.","journal-title":"Cephalalgia"},{"issue":"44","key":"1086_CR32","doi-asserted-by":"publisher","first-page":"10587","DOI":"10.1523\/JNEUROSCI.2211-17.2017","volume":"37","author":"A Melo-Carrillo","year":"2017","unstructured":"Melo-Carrillo A, Strassman AM, Nir RR, et al. Fremanezumab\u2014a humanized monoclonal anti-CGRP antibody\u2014inhibits thinly myelinated (A\u03b4) but not unmyelinated (C) meningeal nociceptors. J Neurosci. 2017;37(44):10587\u201396. https:\/\/doi.org\/10.1523\/JNEUROSCI.2211-17.2017.","journal-title":"J Neurosci"},{"issue":"8","key":"1086_CR33","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/pm\/pnab093","volume":"22","author":"F Cohen","year":"2021","unstructured":"Cohen F, Armand C, Lipton RB, et al. Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxinA in patients with chronic migraine. Pain Med. 2021;22(8):1857\u201363. https:\/\/doi.org\/10.1093\/pm\/pnab093.","journal-title":"Pain Med"},{"issue":"2","key":"1086_CR34","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","volume":"10","author":"AM Blumenfeld","year":"2021","unstructured":"Blumenfeld AM, Frishberg BM, Schim JD, et al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: a retrospective chart review. Pain Ther. 2021;10(2):809\u201326. https:\/\/doi.org\/10.1007\/s40122-021-00264-x.","journal-title":"Pain Ther"},{"key":"1086_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.788159","volume":"12","author":"L Mechtler","year":"2022","unstructured":"Mechtler L, Saikali N, McVige J, et al. Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to onabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine. Front Neurol. 2022;12: 788159. https:\/\/doi.org\/10.3389\/fneur.2021.788159.","journal-title":"Front Neurol"},{"key":"1086_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107200","volume":"215","author":"AS Nandyala","year":"2022","unstructured":"Nandyala AS, Suri H, Dougherty CO, et al. A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine. Clin Neurol Neurosurg. 2022;215: 107200. https:\/\/doi.org\/10.1016\/j.clineuro.2022.107200.","journal-title":"Clin Neurol Neurosurg"},{"issue":"10","key":"1086_CR37","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1111\/head.13638","volume":"59","author":"A Masters-Israilov","year":"2019","unstructured":"Masters-Israilov A, Robbins MS. OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine. Headache. 2019;59(10):1753\u201361. https:\/\/doi.org\/10.1111\/head.13638.","journal-title":"Headache"},{"issue":"9","key":"1086_CR38","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/pm\/pny282","volume":"20","author":"S Quintas","year":"2019","unstructured":"Quintas S, Garc\u00eda-Azor\u00edn D, Heredia P, et al. Wearing off response to onabotulinumtoxinA in chronic migraine: analysis in a series of 193 patients. Pain Med. 2019;20(9):1815\u201321. https:\/\/doi.org\/10.1093\/pm\/pny282.","journal-title":"Pain Med"},{"key":"1086_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jocn.2019.07.043","volume":"69","author":"A Zidan","year":"2019","unstructured":"Zidan A, Roe C, Burke D, et al. OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study. J Clin Neurosci. 2019;69:237\u201340. https:\/\/doi.org\/10.1016\/j.jocn.2019.07.043.","journal-title":"J Clin Neurosci"},{"key":"1086_CR40","doi-asserted-by":"publisher","unstructured":"Ozudogru S, Bartell J, Yuan H, et al. The effect of adding calcitonin gene-related peptide monoclonal antibodies to onabotulinum toxin a therapy on headache burden: a retrospective observational case series. Headache J Head Face Pain 2020;60:1442\u20133. https:\/\/doi.org\/10.1111\/head.13839","DOI":"10.1111\/head.13839"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01086-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01086-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01086-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T16:37:15Z","timestamp":1715877435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01086-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,7]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1086"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01086-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,7]]},"assertion":[{"value":"13 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was completed with funding from a Cleveland Clinic institutional grant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Amira Salim, Elise Hennessy, Claire Sonneborn, Olivia Hogue, Sudipa Biswas, MaryAnn Mays, Aarushi Suneja, Zubair Ahmed, and Ignacio F. Mata have no disclosures to declare relevant to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Cleveland Clinic Institutional Review Board (CC IRB), and due to the use of pre-existing data, the CC IRB waived the written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Due to reasons of patient data sensitivity, the data cannot be found openly available; however, the dataset will be anonymized and made available from the authors upon reasonable request from qualified investigators.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"AS: Conceptualization, methodology, formal analysis, writing\u2014original draft preparation, writing\u2014review and editing, visualization. EH: Writing\u2014original draft preparation, writing\u2014review and editing, visualization. CS: Methodology, formal analysis, writing\u2014review and editing. OH: Methodology, formal analysis, writing\u2014review and editing. SBs: Writing\u2014review and editing. MAM: Writing\u2014review and editing, supervision. AS: Writing\u2014review and editing. ZA: Conceptualization, writing\u2014review and editing, supervision, funding acquisition. IFM: Writing\u2014review and editing, supervision, project administration, funding acquisition.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}